Randomised trial in newly diagnosed Hodgkin's disease: evaluation of drug scheduling (alternating LOPP/EVAP versus LOPP/EVA hybrid) and consolidation radiotherapy

Submission date	Recruitment status	Prospectively registered
01/07/2001	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
01/07/2001	Completed	Results
Last Edited	Condition category	Individual participant data
26/02/2015	Cancer	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

- -

Contact details

UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

Additional identifiers

Protocol serial number BNLI2

Study information

Scientific Title

Randomised trial in newly diagnosed Hodgkin's disease: evaluation of drug scheduling (alternating LOPP/EVAP versus LOPP/EVA hybrid) and consolidation radiotherapy

Study objectives

Evaluation of drug scheduling (alternating LOPP/EVAP versus LOPP/EVA hybrid) and consolidation radiotherapy

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Hodgkin's lymphoma

Interventions

- 1. Regimen A: Chemotherapy, chlorambucil vincristine, procarbazine and prednisolone (LOPP) alternating every 28 days with etoposide, vinblastine, adriamycin and prednisolone (EVAP). A course of chemotherapy is given every 28 days for a minimum of six cycles.
- 2. Regimen B: Chemotherapy, chlorambucil, vincristine, procarbazine and prednisolone, etoposide, vinblastine, adriamycin (LOPP/EVA) repeated every 28 days for a minimum of six cycles.

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s))

Not provided at time of registration

Completion date

31/12/2005

Eligibility

Key inclusion criteria

- 1. Aged over 15 years
- 2. Stage IB, IIB, III or IV Hodgkin's Disease.
- 3. Histologically confirmed Hodgkin's lymphoma
- 4. Free from any potentially life threatening disease other than Hodgkin's Disease
- 5. Lymphangiography or Computed Tomography (CT) scan of the abdomen
- 6. No previous treatment except as an emergency measure

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1999

Date of final enrolment

31/12/2005

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

MRC Clinical Trials Unit

London

United Kingdom

NW1 2DA

Sponsor information

Organisation

Cancer Research UK (CRUK) (UK)

ROR

https://ror.org/054225q67

Funder(s)

Funder type

Charity

Funder Name

Lymphoma Research Trust

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Funder Name

Lisa Lear Fund

Funder Name

Isle of Man Anti-Cancer Association

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?

Participant information sheet 11/11/2025 No Yes